Thrivent Financial for Lutherans Has $4.95 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Thrivent Financial for Lutherans lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 54.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,941 shares of the biotechnology company's stock after selling 42,532 shares during the period. Thrivent Financial for Lutherans owned 0.06% of Ascendis Pharma A/S worth $4,948,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ASND. Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at $60,000. Janus Henderson Group PLC lifted its position in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after buying an additional 267,881 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $19,908,000. Zimmer Partners LP acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $11,646,000. Finally, Maven Securities LTD bought a new position in shares of Ascendis Pharma A/S in the third quarter worth about $7,466,000.

Ascendis Pharma A/S Stock Performance

ASND traded down $3.26 on Friday, reaching $154.68. The company had a trading volume of 289,067 shares, compared to its average volume of 465,148. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37. The stock has a market cap of $9.39 billion, a P/E ratio of -21.79 and a beta of 0.62. The company's fifty day moving average is $143.63 and its 200 day moving average is $136.75.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analyst Weigh In

ASND has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price for the company. Cantor Fitzgerald upped their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. Evercore ISI raised their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.